1 Duffau, H. et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry76, 845-851, doi:10.1136/jnnp.2004.048520 (2005).
2 Smith, J. S. et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol26, 1338-1345, doi:10.1200/JCO.2007.13.9337 (2008).
3 Sanai, N., Polley, M. Y., McDermott, M. W., Parsa, A. T. & Berger, M. S. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg115, 3-8, doi:10.3171/2011.2.JNS10998
10.3171/2011.7.JNS10238 (2011).
4 Jakola, A. S. et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. Jama308, 1881-1888, doi:10.1001/jama.2012.12807 (2012).
5 Soffietti, R. et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol17, 1124-1133, doi:10.1111/j.1468-1331.2010.03151.x (2010).
6 Yordanova, Y. N., Moritz-Gasser, S. & Duffau, H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. J Neurosurg115, 232-239, doi:10.3171/2011.3.JNS101333 (2011).
7 Duffau, H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien)158, 51-58, doi:10.1007/s00701-015-2621-3 (2016).
8 Brown, T. J. et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol2, 1460-1469, doi:10.1001/jamaoncol.2016.1373 (2016).
9 Beiko, J. et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol16, 81-91, doi:10.1093/neuonc/not159 (2014).
10 Esquenazi, Y. et al. The Survival Advantage of "Supratotal" Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. Neurosurgery81, 275-288, doi:10.1093/neuros/nyw174 (2017).
11 Li, Y. M., Suki, D., Hess, K. & Sawaya, R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? J Neurosurg124, 977-988, doi:10.3171/2015.5.JNS142087 (2016).
12 Pessina, F. et al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol135, 129-139, doi:10.1007/s11060-017-2559-9 (2017).
13 Molinaro, A. M. et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol, doi:10.1001/jamaoncol.2019.6143 (2020).
14 Incekara, F., Koene, S., Vincent, A., van den Bent, M. J. & Smits, M. Association Between Supratotal Glioblastoma Resection and Patient Survival: A Systematic Review and Meta-Analysis. World Neurosurg127, 617-624 e612, doi:10.1016/j.wneu.2019.04.092 (2019).
15 Lasocki, A. & Gaillard, F. Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research. AJNR Am J Neuroradiol40, 758-765, doi:10.3174/ajnr.A6025 (2019).
16 Shinozaki, N. et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg114, 1640-1647, doi:10.3171/2010.11.JNS10553 (2011).
17 Tanaka, Y. et al. Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg110, 163-172, doi:10.3171/2008.4.17569 (2009).
18 Iuchi, T. et al. Methionine Uptake and Required Radiation Dose to Control Glioblastoma. Int J Radiat Oncol Biol Phys93, 133-140, doi:10.1016/j.ijrobp.2015.04.044 (2015).
19 Hirono, S. et al. Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. Sci Rep9, 17794, doi:10.1038/s41598-019-54398-2 (2019).
20 Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med352, 987-996, doi:10.1056/NEJMoa043330 (2005).
21 Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol28, 1963-1972, doi:10.1200/JCO.2009.26.3541 (2010).
22 Parsa, A. T. et al. Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg102, 622-628, doi:10.3171/jns.2005.102.4.0622 (2005).
23 Sato, W. et al. Structural Neural Substrates of Reading the Mind in the Eyes. Frontiers in human neuroscience10, 151, doi:10.3389/fnhum.2016.00151 (2016).
24 Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine352, 997-1003, doi:10.1056/NEJMoa043331 (2005).
25 Stupp, R. et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. Jama318, 2306-2316, doi:10.1001/jama.2017.18718 (2017).
26 Chamberlain, M. C. Radiographic patterns of relapse in glioblastoma. J Neurooncol101, 319-323, doi:10.1007/s11060-010-0251-4 (2011).
27 Aldave, G. et al. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-guided surgery. Neurosurgery72, 915-920; discussion 920-911, doi:10.1227/NEU.0b013e31828c3974 (2013).
28 Eyupoglu, I. Y. et al. Supra-complete surgery via dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. Oncotarget7, 25755-25768, doi:10.18632/oncotarget.8367 (2016).
29 Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol10, 459-466, doi:10.1016/S1470-2045(09)70025-7 (2009).
30 Mampre, D. et al. Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes. Br J Neurosurg32, 528-535, doi:10.1080/02688697.2018.1498450 (2018).
31 Altieri, R. et al. Supratotal Resection of Glioblastoma: Is Less More? Surg Technol Int35, 432-440 (2019).
32 Miwa, K. et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry75, 1457-1462, doi:10.1136/jnnp.2003.028480 (2004).
33 Muther, M. et al. 5-Aminolevulinic Acid Fluorescence-Guided Resection of 18F-FET-PET Positive Tumor Beyond Gadolinium Enhancing Tumor Improves Survival in Glioblastoma. Neurosurgery85, E1020-E1029, doi:10.1093/neuros/nyz199 (2019).
34 Albert, N. L. et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol18, 1199-1208, doi:10.1093/neuonc/now058 (2016).
35 Roh, T. H. et al. Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg, 1-7, doi:10.3171/2018.12.JNS182558 (2019).
36 Bell, E., Jr. & Karnosh, L. J. Cerebral hemispherectomy; report of a case 10 years after operation. J Neurosurg6, 285-293, doi:10.3171/jns.1949.6.4.0285 (1949).